Ensign Peak Advisors Inc Sells 93,876 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Ensign Peak Advisors Inc lowered its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 25.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 267,949 shares of the company's stock after selling 93,876 shares during the period. Ensign Peak Advisors Inc owned about 0.31% of Syndax Pharmaceuticals worth $3,542,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Virtus ETF Advisers LLC grew its position in Syndax Pharmaceuticals by 18.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after buying an additional 827 shares during the last quarter. E Fund Management Co. Ltd. raised its position in shares of Syndax Pharmaceuticals by 14.4% during the fourth quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock worth $167,000 after purchasing an additional 1,583 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Syndax Pharmaceuticals by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock valued at $239,000 after purchasing an additional 1,732 shares during the period. R Squared Ltd purchased a new stake in Syndax Pharmaceuticals during the fourth quarter valued at about $26,000. Finally, Y Intercept Hong Kong Ltd boosted its holdings in shares of Syndax Pharmaceuticals by 2.5% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 83,297 shares of the company's stock worth $1,101,000 after buying an additional 1,995 shares during the period.

Syndax Pharmaceuticals Stock Up 12.1%

Shares of NASDAQ:SNDX traded up $1.12 on Tuesday, reaching $10.42. The company had a trading volume of 988,765 shares, compared to its average volume of 1,727,139. The stock has a market capitalization of $896.95 million, a P/E ratio of -2.87 and a beta of 0.82. The stock has a 50-day moving average price of $12.02 and a 200 day moving average price of $13.97. Syndax Pharmaceuticals, Inc. has a twelve month low of $8.58 and a twelve month high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.06. The company had revenue of $20.04 million during the quarter, compared to analyst estimates of $15.88 million. During the same quarter last year, the firm posted ($0.85) earnings per share. The firm's revenue for the quarter was up 1900.0% compared to the same quarter last year. On average, sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on SNDX shares. JPMorgan Chase & Co. boosted their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 20th. StockNews.com raised shares of Syndax Pharmaceuticals to a "sell" rating in a research report on Tuesday, May 6th. Citigroup dropped their price objective on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Finally, Guggenheim reiterated a "buy" rating and set a $32.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $35.91.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).